Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Current Leases (2020 - 2025)

Mereo BioPharma (MREO) has disclosed Current Leases for 6 consecutive years, with $397000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Current Leases fell 46.06% to $397000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $397000.0, a 46.06% decrease, with the full-year FY2024 number at $707000.0, up 8.44% from a year prior.
  • Current Leases was $397000.0 for Q3 2025 at Mereo BioPharma, down from $601000.0 in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $838462.6 in Q4 2021 to a low of $397000.0 in Q3 2025.
  • A 5-year average of $658346.3 and a median of $670500.0 in 2024 define the central range for Current Leases.
  • Peak YoY movement for Current Leases: grew 15.6% in 2023, then plummeted 46.06% in 2025.
  • Mereo BioPharma's Current Leases stood at $838462.6 in 2021, then tumbled by 32.73% to $564000.0 in 2022, then increased by 15.6% to $652000.0 in 2023, then rose by 8.44% to $707000.0 in 2024, then crashed by 43.85% to $397000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Current Leases are $397000.0 (Q3 2025), $601000.0 (Q2 2025), and $747000.0 (Q1 2025).